Novo Nordisk touts blockbuster diabetes data; Gilead lung drug disappoints; Cephalon names Buchi CEO;

@FierceBiotech: Vertex trims a telaprevir study from its slate of hep C work. News | Follow @FierceBiotech

> Novo Nordisk is touting the promising results of two late-stage trials of its experimental diabetes drug Degludec. Analysts estimate the Degludec franchise could generate more than $2 billion in annual sales. Story

> Gilead has halted a clinical trial of its lung drug ambrisentan after an interim analysis showed it was not effective for IPF. The news came as no great surprise. Article

> Cephalon says that J. Kevin Buchi has officially been named CEO in the wake of Frank Baldino's recent death. News

> Gold-plated liposomes an anti-cancer stocking stuffer. Story

And Finally... H. Lundbeck is wrapping trials of nalmafene, which could go on to become the first new treatment of alcoholism Europe's seen in 15 years. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.